Kinpeygo
- Prescription status not stated
- Digestion, stomach, diabetes and nutrition
- Active substance
- Budesonide
- Made by
- Stada Arzneimittel AG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Kinpeygo is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.8 g/g).
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (Budesonide Inhalation Suspension). It describes the substance, not this exact product.
Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity.
In standard in vitro and animal models, budesonide has approximately a 200-fold higher affinity for the glucocorticoid receptor and a 1000-fold higher topical anti-inflammatory potency than cortisol (rat croton oil ear edema assay).
In vitro studies with human liver homogenates have shown that budesonide is rapidly and extensively metabolized.
Budesonide is excreted in urine and feces in the form of metabolites.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-06-10
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Stada Arzneimittel AG |
|---|---|
| Active substance | Budesonide |
| Used in | Digestion, stomach, diabetes and nutrition |
| Classification | A07EA06 · Digestion, stomach, diabetes and nutrition |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Authorised on | 2022-07-15 |
| Last updated by the regulator | 2026-04-23 |
| EMA product number | EMEA/H/C/005653 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.